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Abstract
Purpose—The purpose of this preliminary study was to describe the extent to which providers
used collaborative goal setting and individualized assessment with patients who were newly
prescribed glaucoma medications.
Methods—English-speaking glaucoma suspect patients from six ophthalmology clinics who
were newly prescribed glaucoma medications had their medical visits video-tape recorded and
were interviewed after the visits. The video-tapes were transcribed and coded to examine provider
use of collaborative goal setting and individualized assessment.
Results—Fifty-one patients seeing 12 ophthalmologists participated. Providers gave patients
glaucoma treatment options during 37% of the visits; only five providers gave patients treatment
options Providers asked for patient treatment preferences in less than 20% of the visits; only two
providers asked for patient treatment preferences. Providers were significantly more likely to ask
African American patients for their preferences or ideas concerning treatment than non-African
American patients (Pearson chi-square= 4.1, p=0.04). Providers were also significantly more
likely to ask African American patients about their confidence in using glaucoma medication
regularly than non-African American patients (Pearson chi-square=8.2, p=0.004). Providers asked
about patient views about glaucoma in less than 20% of the visits; five providers asked patients
their views on glaucoma and its treatment. Providers were significantly more likely to ask African
American patients about their views of glaucoma than non-African American patients (Pearson
chi-square=5.62, p=0.02).
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Conclusions—Eye care providers often did not use collaborative goal setting or conduct
individualized assessments of patient views of glaucoma when prescribing treatment for the first
time.
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Glaucoma is a chronic asymptomatic disease like high blood pressure is. In glaucoma, the
goal is to reduce the intraocular pressure in the eye.1 The American Academy of
Ophthalmology Preferred Practice Pattern for Primary Open-Angle Glaucoma states that
intraocular pressure can be lowered by medical treatment (e.g. medications, laser therapy, or
incisional glaucoma surgery).2 Medical treatment and laser therapy are the most commonly
accepted initial interventions to lower IOP in glaucoma patients.3 Each topical class of
glaucoma medications has different side effects profiles and some patients may tolerate
certain side effects better than others.4-8 Additionally, eye drops are often difficult to
administer.7,9,10 Therefore, it becomes important for providers to discuss different treatment
options with patients because some may tolerate certain medications and dosing regimens
better than others.11
Wu et al.1 found that glaucoma self-management behavior was significantly associated with
vision-related quality-of-life. Self-management behavior is critical when managing chronic
diseases.12 Glaucoma is different than other chronic diseases in that eye drop instillation is
usually needed and this is a lifelong disease in which many patients have to manage the
condition over time by taking their prescribed eye drops with the ultimate goal of constant
reduction of intraocular pressure and vision preservation.1. This chronic nature of the
disease is compounded by potential side effects.11 One framework that has been applied to
improving self-management behavior in individuals with chronic diseases is the Resources
and Supports for Self-Management (RSSM).12 This framework emphasizes two key
components that are important for providers to use when patients are newly diagnosed with
a chronic disease: (1) individualized assessment and (2) collaborative goal setting.
Individualized assessment involves exploring the patient's personal and cultural perspective
on the chronic disease and how it will impact their life.12,13 Conducting an individualized
assessment with newly diagnosed glaucoma patients might be important to better
understanding patients’ views of glaucoma and glaucoma treatment options, which is
important since these views could impact patient adherence. Collaborative goal setting
involves empowering patients and asking for their input when treatment decisions are being
made.12 Collaborative goal setting is being applied in several different disease states such as
cardiac rehabilitation,14,15 asthma,16 osteoporosis ,17 psychiatry,18 and diabetes.13,19 Since
there are different treatment choices for the initial treatment of glaucoma such as laser
therapy or medications (prostaglandin analogs, beta-blockers), engaging in collaborative
goal setting can help eye care providers pick the treatment options that are most favored by
the patients.
To our knowledge, no one has previously examined the extent to which eye care providers
utilize collaborative goal setting and conduct an individualized assessment when prescribing
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glaucoma medications for the first time. Therefore, the purpose of our study was to conduct
a preliminary study to examine: (a) the extent to which providers used collaborative goal
setting and individualized assessment with patients who are newly prescribed glaucoma
medications and (b) how patient age, gender, race, and literacy are associated with whether
providers used collaborative goal setting and individualized assessment.
METHODS
Procedure
English-speaking adult glaucoma suspect and glaucoma patients were enrolled at six
geographically distinct ophthalmology clinics located in four states. Two sites were private
offices and four were affiliated with academic ophthalmology departments. At each site,
clinic staff referred eligible patients to research assistants who were based at the clinics.
Written patient and provider consent was obtained. The research assistant administered the
Mental Status Questionnaire after consent was obtained. This 10-item scale assesses
patients’ competence to participate in the research. It has approximately the same sensitivity
and specificity as the Folstein Mini-Mental Status Examination, but it is easier and faster to
administer.20 Patients who make at least five errors were ineligible. Two patients were
ineligible.
Providers completed a short demographic questionnaire after providing consent. The
patient's medical visit was video-tape recorded. Video-tapes were kept if they fit into one of
two criteria: (a) the patient was diagnosed with glaucoma and glaucoma medications were
prescribed for the first time or (b) patients were already on glaucoma medications. Patients
were interviewed after their medical visits. This manuscript focuses on those 51 individuals
who were prescribed glaucoma medications for the first time. The study was approved by
the following institutional review boards: University of North Carolina, Duke University,
Emory University, and the University of Utah.
Measurement
Socio-Demographic Characteristics—Patient age was measured as a continuous
variable. Self-reported patient race was measured as a categorical variable (White, African
American, Asian, Native American, and Hispanic). We then recoded into African American
and non-African American since the majority of the non-African American patient sample
was White (91 %). Gender was measured as a dichotomous variable. Each patient received
the Rapid Estimate of Adult Literacy in Medicine (REALM). This is a validated, rapid
screening instrument designed to identify patients who have difficulty reading common
medical and lay terms that are routinely used in patient education materials.21 We choose
the REALM because it has high face validity and high criterion validity, it has been well
received by patients, and it only takes two to three minutes to administer and score.21 Patient
scores on the REALM correspond to reading levels, which were dichotomized (score of
0-60=eighth grade and below, 61-66=ninth grade and above). Whether the patient has
insurance and whether the patient has prescription drug insurance were measured as a
dichotomous variables (yes/no).
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Physician age and years since graduating from medical school were measured as continuous
variables and physician gender was measured as a dichotomous variable. However, since
physician age and years since graduating from medical school were so highly correlated
(Pearson correlation= −0.94, p=0.000), we only used physician age in our analyses. Self-
reported physician race was measured as a categorical variable (White, African American,
Asian, Native American, and Hispanic).
Communication Measures—Medical visit video-tapes were transcribed into text
verbatim with identifiers removed. A detailed coding tool was developed over a one-year
period using aspects of the key resources and supports for self-management model (RSSM)
as a guide.12,13,19 The transcripts were reviewed by a research assistant who met twice a
month with the investigators to develop and refine the coding rules.
Using the coding tool for transcribed medical visits, coders recorded whether the provider
participated in the following aspects of collaborative goal setting: (a) patient is given choices
about treatment, (b) provider asks for preferences or ideas on treatment, (c) provider asks
patient to talk about treatment goals, and (d) patient helps set treatment goals. The coders
also recorded whether the provider conducted the following aspects of an individualized
assessment: (a) asks the patient about their views of glaucoma and/or its treatment, asks the
patient about how glaucoma will impact their life, (b) asks about confidence in using
glaucoma medication regularly, and (c) asks about intention to adhere to glaucoma
medications.
Three research assistants coded 25 of the same transcripts throughout the study period to
assess inter-coder reliability which was calculated using inter-rater correlations. Inter-rater
reliability was 0.82 for giving the patient treatment choices and 0.92 for the doctor asking
for patient preferences for treatment. There was not enough variability to calculate reliability
for whether the provider asked the patient to discuss treatment goals and whether the patient
helped set the treatment goals because these communication behaviors occurred so
infrequently, but there was 100% agreement among the coders. Inter-rater reliability was
0.80 for whether the provider asked the patient about their views about glaucoma or its
treatment and 0.70 for whether the patient felt confident in taking medication regularly.
There was not enough variability to calculate reliability for whether the provider asked the
patient how glaucoma might impact their life and the patient's intention to adhere to
treatment because each occurred so infrequently, but there was 100% agreement among the
coders.
Analysis
We set the a priori level of statistical significance at p < 0.05. We first present descriptive
statistics and describe the extent to which physicians utilized collaborative goal setting and
individualized assessment with patients. We also present qualitative examples of the
communication techniques used by providers for collaborative goal setting and
individualized assessments with their patients. Finally, we present the extent to which each
physician used collaborative goal setting and individualized assessment.
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Fifteen physicians who cared for glaucoma patients agreed to participate in the study; one
physician refused to participate for a participation rate of 94%. Fourteen physicians were
White and one was African American. Ten physicians were male (66.7%). Physician age
ranged from 26 to 66 years (mean 40.8 years, standard deviation 11.7 years). Twelve of
these physicians cared for the 51 patients who were newly prescribed glaucoma medications.
Eighty-six percent of eligible patients participated in the study (N=279). Eighteen percent of
patients (N=51) were prescribed glaucoma medications for the first time and this analysis
focuses on these individuals. Table 1 presents the patient demographics. Thirty-five percent
of the sample was male and 27.5% were African American.
Provider Use of Collaborative Goal Setting
Table 2 presents the extent to which providers engaged in collaborative goal setting.
Providers gave patients choices about treatment during 37% of the visits (N=19). As shown
in Table 3, only five providers gave patients treatment choices. Out of the 19 visits where
providers gave patients treatment choices, 13 of these visits were with one provider.
Collaborative goal setting could involve providers giving patients a choice of medications
versus other treatment options such as laser therapy or it could involve giving the patient a
choice between medications. An actual example of the provider giving the patient several
treatment options is presented below (D=doctor, P=patient).
D-And the two options that are kind of first line treatment are laser or eye drops.
D-Um, the benefit of the laser is that it would um, not require you to put something in your
eye every day.
P-(Nods head yes).
D-Um and its pretty well tolerated laser. And it works pretty well.
D-Most people do respond.
P-(Nods head yes).
D-But some people don't respond.
D-Um, the downside of the laser is that it wears off over time.
D- So about five years probably fifty percent or maybe a little bit more of people aren't
responding to the laser.
P-(Nods head yes).
D-And then you have to think about the next step which would be to repeat the laser or to
um, go to eye drops. Okay?
D-So um, and then the other option is drops.
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D-The benefit of eye drops is um, you know, it's not permanent.
D-Um in the sense that we can stop them and the fact is they're reversible.
D-Um the downside to them is that they can have side effects. And that does require you to
take the drops on a regular basis. Okay?
P-(Nods head yes).
D-So there are, there's four main kinds of drops that we, that we can give just for glaucoma.
And two of them are dosed just once a day so those are the ones I typically start with
because it's easier to remember to do something once a day rather than more than once a
day.
P-(Nods head yes).
So what do you think?
P-I mean I'll go with the drops but uh, why would you even take them more than once a day
though?
D-So, the, the two other drops that aren't once a day are either two or three times a day. And
the reason they're dosed that way is because the uh, timeframe which they soak in and sort
of soak out of the body, kind of wear off, is shorter. So it um, they, they just don't last a
whole day. They don't cover your treatment for a whole day so you have to dose them more
often.
P-Okay.
In contrast, below is an example of a provider not giving a patient a choice about glaucoma
treatment options. In the excerpt below, the doctor tells the patient he/she is going to use
Travatan and does not present any alternatives. The doctor continues to talk without giving
the patient a chance to say anything other than “Okay”.
D-One of the issues is that glaucoma doesn't have any symptoms. It doesn't hurt and people
don't know they have it. And it's a slow gradual disease. And one of the best things to do is
head it off before it starts. By using eye drops to lower your eye pressure, um, we know that
we can arrest the progression of the disease. At the very least slow it down, but mostly we
just stop it from getting worse. Okay?
P-Ok.
D-Um, so when we talk about taking eye drops, you're going to using Travatan to lower
your eye pressure. This is a drug that um, you take once a day. You're gonna take it in both
eyes, and we sort of recommend that you take it before bedtime at night. Because I've said
most people's eye pressures are highest in the morning. And this works best a few hours
after you take it, so it helps us control that high spike up in the morning so, keep your
pressures more consistent as well as just lowering it.
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Providers were significantly more likely to give younger patients (t-test= −2.20, p=0.03) and
male patients (Pearson chi-square=3.98, p=0.04) choices about glaucoma treatment. These
borderline statistically significant results should be interpreted with caution. Providers gave
55% of male patients choices about glaucoma treatment compared to 27% of females.
Health literacy and race were not significantly associated with whether the provider gave
patients choices about treatment.
The provider asked for patient preferences or ideas about treatment in less than 20% of the
visits. As shown in Table 3, only 2 providers asked patients for their preferences or ideas
concerning treatment. Providers were significantly more likely to ask African American
patients for their preferences or ideas on treatment than non-African American patients
(Pearson chi-square= 4.1, p=0.04). These borderline statistically significant results should be
interpreted with caution. Providers asked 35.7% of African Americans their treatment
preferences compared to 11% of non-African Americans.
Providers Conducting an Individualized Assessment about Patient Views on Glaucoma
and Its Treatment
Table 2 also illustrates the extent to which providers conducted individualized assessments.
Providers asked patient views about glaucoma and/or its treatment during only 16% of
visits. One provider stated to a patient, “Glaucoma can be treated but I think the first
question is: What is Glaucoma? How would you explain that to someone?” As shown in
Table 3, only five providers asked patients about their views on glaucoma and its treatment.
Providers were significantly more likely to ask African American patients about their views
of glaucoma and/or its treatment than non-African American patients (Pearson chi-
square=5.62, p=0.02). They asked 36% of African American patients about their views on
glaucoma and/or its treatment compared to 8% of non-African American.
Providers asked about patient confidence in using glaucoma medication regularly during
5.9% of visits. One provider asked a patient “Do you feel like you're going to be confident
to do this every day?” As shown in Table 3, only two providers asked about patient
confidence in using glaucoma medications regularly. Providers were significantly more
likely to ask younger patients about their confidence in using glaucoma medications
regularly than older patients (t-test= −2.09, p=0.04). Providers were also significantly more
likely to ask African American patients about their confidence in using glaucoma
medication regularly than non-African American patients (Pearson chi-square=8.2,
p=0.004). These borderline statistically significant results should be interpreted with caution.
Providers asked 21% of African American patients and no non-African American patients
about their confidence in using glaucoma medications on a regular basis. Providers did not
ask about how glaucoma would impact the patient's life during any visits. Providers did not
ask about the patient's intention to adhere to glaucoma medications in the future during any
visits.
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Collaborative goal setting did not occur very often when patients were newly started on
treatment for glaucoma. Providers were significantly more likely to ask African American
patients about their treatment preferences than non-African American patients. This may be
because providers were aware that glaucoma is the leading cause of irreversible blindness
among African Americans 22 and prior work has found that African Americans are less
adherent to their glaucoma medications than White patients.9,23,24 However, the results of
our preliminary study need to be interpreted with care, because very few providers even
engaged in collaborative goal setting.
Providers did not ask patients about treatment goals nor engage any patients in helping to set
treatment goals during any of the visits. Providers should consider communicating with
patients about their treatment goals. Collaborative goal setting or shared decision-making is
important because it allows the patient to be a partner in setting treatment goals which can
motivate them to better manage their glaucoma by following the agreed upon treatment plan
and may drastically improve adherence.12
Rarely did providers conduct individualized assessments with patients. Individualized
assessments allow providers to explore the patient's perspective on glaucoma and how it will
impact their life.12,13 They were significantly more likely to ask African American patients
about their views of glaucoma and about their confidence in using glaucoma medications
regularly than non-African American patients. This could be because prior work has found
that African Americans are less adherent to their glaucoma medications than White
patients.9, 23,24 Providers should make sure to ask all patients, regardless of their race about
their views about glaucoma as well as its treatment.
Providers did not ask any patients how glaucoma impacted their lives. This is important for
providers to ask about since patients newly diagnosed with glaucoma will have to live with
the condition and start regularly using the treatment for it or have surgery. Understanding
the patient's perspective about how glaucoma will impact their life can help providers know
what needs to be done to help the patient live with and self manage their glaucoma.
Also, providers should assess patient confidence in using medication regularly and patient
intention to adhere in the future. This could help providers understand potential barriers that
a patient may have to starting treatment. If a patient is not confident in using glaucoma
medication regularly or if they do not intend to adhere, these are important factors for the
provider to know about, because the provider might then consider treatment options.
The Resources and Supports for Self-Management (RSSM)12 emphasizes two key strategies
that are important for providers to use when patients are newly diagnosed with a chronic
diseases-individualized assessment and collaborative goal setting session. One way to ensure
this is to cover the following with patients when newly prescribing treatment for glaucoma:
(a) ensure a shared understanding of the patient's illness, (b) present treatment options, (c)
discuss the patient's values and lifestyle factors, and (d) present a clear statement of
recommended treatment options and encourage patient choice.25,26 The American Academy
of Ophthalmology's Preferred Practice Pattern for Primary Open-Angle Glaucoma states
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“the patient and ophthalmologist together decide on a practical and feasible regimen to
follow in terms of dosing, cost, and adherence in the context of the patient's age and
preferences”.11 Involving patients in decision-making has been associated with a reduction
in health care costs and utilization.27 Future research should investigate whether other types
of eye care providers such as optometrists or osteopathic physicians are more likely to use
collaborative goal setting and conduct individualized assessments when prescribing
treatments to patients.
This study has several limitations. Our preliminary results should be interpreted with care,
because a limited number of providers engaged in individualized assessments. Providers and
patients both knew the visit was being recorded but they did not know the study hypotheses.
Selection bias could be another limitation since the ancillary staff did not track the
characteristics of the patients who declined to speak with the research assistant to learn more
about the study. Another limitation is the small sample size (51 patients seeing 12 providers)
and the limited use of collaborative goal setting and individualized assessment by only a few
providers, which caused us to be unable to conduct multivariable analyses. However, a
strength of the sample is that it is comprised of patients who were newly diagnosed with
glaucoma and prescribed glaucoma medications. Another limitation is that we did not ask
patients if they wanted to be involved in treatment decisions so we could not examine how
this was associated with provider communication behaviors. Despite these limitations, the
study presents new information on the extent to which collaborative goal setting was used
and the extent to which providers conducted individualized assessments on patient views of
glaucoma when patients were newly diagnosed with glaucoma and prescribed glaucoma
medications for the first time.
CONCLUSION
In this preliminary study, eye care providers did not often use collaborative goal setting or
conduct individualized assessments of patient views of glaucoma and its treatment when
prescribing treatment for the first time to glaucoma patients.
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Table 1
Patient characteristics who are newly started on a glaucoma medication (N=51).
Percent (N)
Gender
    Male 35.3 (18)
    Female 64.7 (33)
Race
    African American 27.5 (14)
    Non-African American 70.6 (36)
    Missing 1.9(1)
REALM
    Eighth grade or lower 11.8 (6)
    Ninth grade or higher 88.2 (45)
Has health insurance
    Yes 96.1 (49)
    No 3.9 (2)
Has prescription drug insurance
    Yes 94.1 (48)
    No 5.9 (3)
Range; Mean (Standard Deviation)
Age in years 25-93; 63.7 (15.9)
Years of education 7-25; 15.6 (3.8)
REALM=Rapid Estimate of Adult Literacy in Medicine
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Table 2
Extent to which physicians engaged in collaborative goal setting and individualized assessment with patients
who were prescribed glaucoma medications for the first time (N=51)
Percent (N)
Collaborative goal setting
Patient is given choices about treatment 37.3 (19)
Provider asks for preferences or ideas on treatment 17.6 (9)
Provider asks patient to talk about treatment goals 0 (0)
Patient helps set treatment goals 0 (0)
Individualized assessment
Asks patient about views of glaucoma and/or its treatment 15.7 (8)
Asks the patient about how glaucoma will impact their life 0 (0)
Asks about confidence in using medication regularly 5.9 (3)
Asks about intention to adhere in future 0 (0)
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Table 3
Characteristics of patients who were newly prescribed a glaucoma medication and use of collaborative goal
setting and individualized assessment by physician.




























Provider A1 61 year-old
Male
87.5% (7/8) 0% (0/8) 0% (0/8) 0% (0/8) 12.5% (1/8) 0% (0/8)
Provider A2 31 year-old
female
100% (1/1) 0% (0/1) 100% (1/1) 0% (0/1) 0% (0/1) 0% (0/1)
Provider A3 28 year-old
female
100% (2/2) 100% (2/2) 0% (0/2) 0% (0/2) 50% (1/2) 100% (2/2)
Clinic B
Provider B1 34 year-old
male
50% (4/8) 0% (0/8) 37.5% (3/8) 0% (0/8) 25% (2/8) 0% (0/8)
Provider B2 66 year-old
male
0% (0/2) 0% (0/2) 0% (0/2) 0% (0/2) 0% (0/2) 0% (0/2)
Provider B3 35 year-old
female
100% (4/4) 0% (0/4) 0% (0/4) 0% (0/4) 0% (0/4) 0% (0/4)
Clinic C
Provider C1 35 year-old
female
100% (1/1) 0% (0/1) 0% (0/1) 0% (0/1) 0% (0/1) 0% (0/1)
Provider C2 45 year-old
male
100% (1/1) 0% (0/1) 0% (0/1) 0% (0/1) 0% (0/1) 0% (0/1)
Clinic D
Provider D1 35 year-old
female
25% (1/4) 50% (2/4) 25% (1/4) 0% (0/4) 50% (2/4) 25% (1/4)
Provider D2 46 year-old
male
50% (7/14) 50% (7/14) 92.8% (13/14) 57.1% (8/14) 14.3% (2/14) 0% (0/14)
Clinic E
Provider E3 42 year-old
male
100% (4/4) 75% (3/4) 25% (1/4) 25% (1/4) 0% (0/4) 0% (0/4)
Clinic F
Provider F1 49 year-old
male
50% (1/2) 0% (0/2) 0% (0/2) 0% (0/2) 0% (0/2) 0% (0/2)
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